Iris Dorbian
Seattle-based Omnidian, a provider of residential and C&I solar system protection plans and performance guarantees, has secured $15 million in funding. IA Capital led the round.
Vancouver, British Columbia-based Inventys, a carbontech company, has raised $10 million in funding. The investors were OGCI Climate Investments, BDC Cleantech Practice, Husky Energy, The Roda Group and Chevron Technology Ventures.
Houston-based Data Gumbo Corp, a blockchain-as-a-service platform provider, has named Sergio A. Tuberquia as chief commercial officer. Prior to joining Data Gumbo, Tuberquia was founder and CEO of Equipcast. Data Gumbo's backers include Saudi Aramco Energy Ventures and Equinor Technology Ventures.
DTCP has closed its second venture and growth fund at $350 million. The fund's limited partners include Deutsche Telekom, HarbourVest Partners and Neuberger Berman. The fund will invest between $5 million and $50 million in enterprise SaaS companies.
UK-based Motorway, a used car marketplace, has raised 11 million pounds in Series A funding. Marchmont Ventures led the round.
Button, a mobile commerce platform, has raised $30 million in Series C funding. Icon Ventures led the round with participation from Capital One Ventures, Redpoint Ventures, Norwest Venture Partners and DCM Ventures. In addition to the funding, Jeb Miller, a general partner of Icon Ventures, will be joining Button's board of directors.
Chrysalix Venture Capital has made an investment in Emeryville, California-based Feasible Inc, a battery analytics platform company. No financial terms were disclosed.
New York-based Phreesia, a healthcare software company, has filed for an IPO. The number of shares that will be sold as well as the stock's pricing terms have yet to be set. The company plans on trading the stock on the New York Stock Exchange under the ticker symbol "PHR." J.P. Morgan, Wells Fargo Securities and William Blair are the lead underwriters. Phreesia's backers include LLR Partners, HLM Venture Partners, Polaris Partners, Ascension Ventures, Echo Health Venture and Blue Cross Blue Shield Venture Partners.
Singapore-based Tin Men has raised over $20.8 million for its debut venture fund, according to an SEC filing. No target was listed in the document.
San Diego-based AFYX Therapeutics, a clinical stage biopharmaceutical company, has secured $13 million in convertible loan financing. Sofinnova Ventures was the lead investor.